Neurothera Labs and Clearmind Medicine File Israeli Patent Application for Non-Hallucinogenic Depression Treatment
TL;DR
Neurothera Labs' new patent filing for MEAI and PEA combination therapy could provide a competitive edge in the $280 million depression treatment market.
The therapy combines MEAI and N-Acylethanolamines like PEA, targeting depression through preclinical data showing efficacy while preserving natural reward pathways.
This innovative depression treatment could improve quality of life for millions worldwide affected by major depressive disorder, a leading cause of disability.
Neurothera Labs' 13th patent filing combines MEAI with PEA, expanding their portfolio for treating depression, addiction, and obesity through novel drug combinations.
Found this article helpful?
Share it with your network and spread the knowledge!
Neurothera Labs Inc., a clinical-stage biotech company and wholly-owned subsidiary of SciSparc Ltd., announced that Clearmind Medicine Inc. has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting depression treatment. This patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine, marking a significant advancement in the development of novel mental health therapeutics.
The timing of this development is particularly relevant given the global burden of depression. According to the World Health Organization, major depressive disorder affects more than 280 million people worldwide and remains one of the leading causes of disability. The limited availability of innovative treatment options underscores the importance of new therapeutic approaches that could potentially address the shortcomings of existing depression treatments.
This new Israeli patent filing expands the joint intellectual property portfolio developed through the Neurothera-Clearmind collaboration. To date, 13 patents have been filed under the partnership, focusing on MEAI and N-Acylethanolamines combinations for various conditions including alcohol use disorder, cocaine addiction, obesity and weight loss, and now depression. The growing portfolio demonstrates the versatility of the MEAI platform and its potential applications across multiple therapeutic areas.
Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways, suggesting a potentially favorable safety profile compared to existing treatments. The combination with PEA, an endogenous fatty acid amide, represents an innovative approach that could offer new mechanisms of action for depression treatment without the hallucinogenic effects associated with some emerging psychiatric treatments.
The implications of this development extend beyond the immediate patent filing. As Neurothera advances MEAI-based treatments toward clinical development, this represents progress in the company's mission to develop novel, science-backed solutions for some of the world's most challenging mental health conditions. The collaborative approach between Neurothera and Clearmind Medicine exemplifies how partnerships can accelerate innovation in the biopharmaceutical sector, potentially bringing new treatment options to patients faster.
For investors and stakeholders following the company's progress, additional information identifying risks and uncertainties are contained in the filings by the Company with the Canadian securities regulators, which filings are available at https://www.sedarplus.ca. The ongoing expansion of the intellectual property portfolio through strategic collaborations positions Neurothera Labs at the forefront of developing novel CNS therapeutics for underserved health conditions.
Curated from NewMediaWire
